[Biomarker for molecular targeting therapy against renal cell carcinoma].
作者信息
Mizuno Ryuichi, Oya Mototsugu
机构信息
Department of Urology, Keio University School of Medicine, Tokyo, Japan
出版信息
Gan To Kagaku Ryoho. 2012 Jan;39(1):39-42.
PMID:22454982
Abstract
摘要
相似文献
1
[Biomarker for molecular targeting therapy against renal cell carcinoma].
Gan To Kagaku Ryoho. 2012 Jan;39(1):39-42.
2
[Biomarkers of response to molecular targeted therapy in renal cell carcinoma].
Gan To Kagaku Ryoho. 2011 Jul;38(7):1088-91.
3
[The pathologist's role in the neoadjuvant strategy of renal-cell carcinoma].
Ann Pathol. 2011 Dec;31(6):466-71. doi: 10.1016/j.annpat.2011.10.004. Epub 2011 Nov 29.
4
Is tumor response important for renal carcinoma?
Eur Urol. 2011 Jan;59(1):16-7. doi: 10.1016/j.eururo.2010.10.010. Epub 2010 Oct 15.
5
[Molecular targeted therapy for advanced renal cell carcinoma].
Gan To Kagaku Ryoho. 2010 Jul;37(7):1208-13.
6
[Second-line treatment of advanced renal cell carcinoma after first-line targeted therapy].
Gan To Kagaku Ryoho. 2011 Jun;38(6):907-10.
7
Molecularly targeted agents for renal cell carcinoma: the next generation.
Clin Adv Hematol Oncol. 2010 May;8(5):357-60, 361-4.
8
Temsirolimus (Torisel) for advanced renal cell carcinoma.
Med Lett Drugs Ther. 2007 Dec 17;49(1276):103-4.
9
[Third-line therapy for metastasized renal cell carcinoma: a randomized, multicenter non-blinded phase III study to compare safety and effectiveness of TF1258 versus sorafenib in patients with metastasized renal cell carcinoma following failure of antiangiogenic (VEGF targeted and mTOR inhibition) therapy (GOLD-AN 31/11 of the Working Group Urological Oncology)].
Urologe A. 2011 Oct;50(10):1319-21. doi: 10.1007/s00120-011-2744-y.
10
Medullary renal cell carcinoma and response to therapy with bortezomib.
J Clin Oncol. 2006 Mar 20;24(9):e14. doi: 10.1200/JCO.2005.05.0344.
Zotero 插件